LDS/Medical Tests/Zolpidem, Serum

Zolpidem, Serum

Zolpidem is the prototype drug of a class of sedative-hypnotic drugs that are derivatives of imidazopyridine. Although zolpidem is not a benzodiazepine drug, it is typically considered to be benzodiazepine-like. For example, like the benzodiazepine class of drugs, zolpidem exerts its activity through interaction with the GABAA receptor. Likewise, the benzodiazepine antagonist flumazenil may be used to reverse symptoms of zolpidem overdose. However, zolpidem does not exhibit the anxiolytic or anticonvulsant properties of benzodiazepine drugs, unless used in extremely high doses. The typical route of administration is oral or sublingual. The half-life of immediate release zolpidem is 1.4-4 hours; longer with extended release formulations. Zolpidem is inactivated by metabolism and approximately 70% of a single dose appears in the urine within 4 days of administration. The primary metabolite is a carboxylic acid derivative. Common side effects: headache, daytime drowsiness, amnesia, dizziness, ataxia, confusion, hostility, irritability, and vivid or disturbing dreams. Overdose effects include shallow respiration, deep sedation, clammy skin, dilated pupils, weak and rapid pulse, coma, and possible death. Zolpidem can be analyzed in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.
  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A qualitative positive result indicates only the presence of Zolpidem and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method. An unexpected negative result could reflect inadequate specimen handling.

Therapeutic levels: 0.1-0.2 mg/L
Toxic levels: Data not available

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges

Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection or laboratory, whether the test is a qualitative method or a quantitative method. The testing laboratory cut-off range is listed on the patient report.

Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Thin Layer Chromatography (TLC). Immunoassays (IA) for zolpidem are not available. Some methods will also detect the carboxylic acid and/or other zolpidem metabolites.

Serum (SST) or plasma (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9,* and *CYP2C19* variants could guide drug and dose selection. Supportive testing such as liver profile, kidney profile, comprehensive metabolic panel, CBC (if overdose), and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Seal Beach, CA: Biomedical Publications; 2011.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.